Small cell lung cancer: From molecular biology to novel therapeutics

Journal of Experimental Therapeutics and Oncology

Volumn 3, Issue 6, 2003, Pages 305-318

  Pisick, Evan ^a   Jagadeesh, Simha ^b   Salgia, Ravi ^b,c  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

Chemotherapy; Molecular biology; Novel therapeutics; Small cell lung cancer

Indexed keywords

ANGIOSTATIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN DERIVATIVE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; DOXORUBICIN; ENDOSTATIN; ETOPOSIDE; FCE 26644; FUMAGILLOL CHLOROACETYLCARBAMATE; GEMCITABINE; IMATINIB; IRINOTECAN; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; MONOCLONAL ANTIBODY; NAVELBINE; PACLITAXEL; PRINOMASTAT; PROTEIN TYROSINE KINASE; REBIMASTAT; SURAMIN; TANOMASTAT; TAXANE DERIVATIVE; TOPOTECAN; UNCLASSIFIED DRUG; VINCRISTINE;

CANCER CHEMOTHERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER SURGERY; CELL FUNCTION; CHROMOSOME 3P; CLINICAL TRIAL; DISEASE SEVERITY; HUMAN; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; META ANALYSIS; METASTASIS POTENTIAL; MOLECULAR BIOLOGY; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; REVIEW; THORAX CANCER; TUMOR SUPPRESSOR GENE;

CARCINOMA, SMALL CELL; COMBINED MODALITY THERAPY; HUMANS; LUNG NEOPLASMS;

EID: 0346096758     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1533-869X.2003.01103.x     Document Type: Review

References (144)

1. Bonfill X, Moreno C, Prada G, Rivero E, Rue M. Lung cancer mortality among males of Catalonia and Spain compared with other European countries between 1975-1977 and 1987-1989. Int J Cancer 65: 751-754, 1996.
2. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 52: 23-47, 2002.
3. Strauss GM, Kwiatkowski DJ, Harpole DH, Lynch TJ, Skarin AT, Sugarbaker DJ. Molecular and pathologic markers in stage I non-small-cell carcinoma of the lung. J Clin Oncol 13: 1265-1279, 1995.
4. Devereux TR, Taylor JA, Barrett JC. Molecular mechanisms of lung cancer. Interaction of environmental and genetic factors. Giles F. Filley Lecture. Chest 109: 14S-19S, 1996.
5. Hibi K, Takahashi T, Yamakawa K, et al. Three distinct regions involved in 3p deletion in human lung cancer, Oncogene 7: 445-449, 1992.
6. Whang-Peng J, Bunn PA Jr, Kao-Shan CS, Lee EC, Carney DN, Gazdar A, Minna JD. A nonrandom chromosomal abnormality, del 3p(14-23), in human small cell lung cancer (SCLC). Cancer Genet Cytogenet 6: 119-134, 1982.
7. Otterson G, Lin A, Kay F. Genetic etiology of lung cancer. Oncology (Huntingt) 6: 97-104, 107; discussion 108: 111-102, 1992.
8. Kok K, Osinga J, Carritt B, et al. Deletion of a DNA sequence at the chromosomal region 3p21 in all major types of lung cancer. Nature 330: 578-581, 1987.
9. Naylor SL, Johnson BE, Minna JD, Sakaguchi AY, Loss of heterozygosity of chromosome 3p markers in small-cell lung cancer. Nature 329: 451-454, 1987.
10. Balsara BR, Testa JR. Chromosomal imbalances in human lung cancer. Oncogene 21: 6877-6883, 2002.
11. Sozzi G, Veronese ML, Negrini M, et al. The FHIT gene 3p14.2 is abnormal in lung cancer. Cell 85: 17-26, 1996.
12. Ji L, Fang B, Yen N, Fong K, Minna JD, Roth JA. Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad (FHIT) gene overexpression. Cancer Res 59: 3333-3339, 1999.
13. Kok K, Naylor SL, Buys CH. Deletions of the short arm of chromosome 3 in solid tumors and the search for suppressor genes. Adv Cancer Res 71: 27-92, 1997.
14. Roche J, Boldog F, Robinson M, et al. Distinct 3p21.3 deletions in lung cancer and identification of a new human semaphorin. Oncogene 12: 1289-1297, 1996.
15. Sekido R, Takagi T, Okanami M, Moribe H, Yamamura M, Higashi Y, Kondoh H. Organization of the gene encoding transcriptional repressor deltaEF1 and cross-species conservation of its domains. Gene 173: 227-232, 1996.
16. Latif F, Tory K, Gnarra J, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260: 1317-1320, 1993.
17. Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3 Nat Genet 25: 315-319, 2000.
18. Burbee DG, Forgacs E, Zochbauer-Muller S, et al. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 93: 691-699, 2001.
19. Kaelin WG Jr. The p53 gene family. Oncogene 18: 7701-7705, 1999.
20. Tokino T, Nakamura Y. The role of p53-target genes in human cancer. Crit Rev Oncol Hematol 33: 1-6, 2000.
21. Sidransky D, Hollstein M, Clinical implications of the p53 gene. Annu Rev Med 47: 285-301, 1996.
22. Knudson AG Jr, Hereditary cancers disclose a class of cancer genes. Cancer 63: 1888-1891, 1989.
23. Kaelin WG Jr. Recent insights into the functions of the retinoblastoma susceptibility gene product. Cancer Invest 15: 243-254, 1997.
24. Flemington EK, Speck SH, Kaelin WG Jr. E2F-1-mediated transactivation is inhibited by complex formation with the retinoblastoma susceptibility gene product. Proc Natl Acad Sci USA 90: 6914-6918, 1993.
25. Helin K, Harlow E, Fattaey A. Inhibition of E2F-1 transactivation by direct binding of the retinoblastoma protein. Mol Cell Biol 13: 6501-6508, 1993.
26. Lemaitre JM, Buckle RS, Mechali M. c-Myc in the control of cell proliferation and embryonic development. Adv Cancer Res 70: 95-144, 1996.
27. Prins J, De Vries EG, Mulder NH, The myc family of oncogenes and their presence and importance in small-cell lung carcinoma and other tumour types. Anticancer Res 13: 1373-1385, 1993.
28. Noguchi M, Hirohashi S, Hara F, Kojima A, Shimosato Y, Shinkai T, Tsuchiya R. Heterogenous amplification of myc family oncogenes in small cell lung carcinoma. Cancer 66: 2053-2058, 1990.
29. Brennan J, O'Connor T, Makuch RW, et al. myc family DNA amplification in 107 tumors and tumor cell lines from patients with small cell lung cancer treated with different combination chemotherapy regimens. Cancer Res 51: 1708-1712, 1991.
30. Korsmeyer SJ. Regulators of cell death. Trends Genet 11: 101-105, 1995.
31. Hale AJ, Smith CA, Sutherland LC, Stoneman VE, Longthorne VL, Culhane AC, Williams GT. Apoptosis: molecular regulation of cell death. Eur J Biochem 236: 1-26, 1996.
32. Kaiser U, Schilli M, Haag U, Neumann K, Kreipe H, Kogan E, Havemann K. Expression of bcl-2-protein in small cell lung cancer. Lung Cancer 15: 31-40, 1996.
33. Jiang SX, Sato Y, Kuwao S, Kameya T. Expression of bcl-2 oncogene protein is prevalent in small cell lung carcinomas. J Pathol 177: 135-138, 1995.
34. Brambilla E, Negoescu A, Gazzeri S, Lantuejoul S, Moro D, Brambilla C, Coll JL. Apoptosis-related factors p53, Bcl2, and Bax in neuroendocrine lung tumors. Am J Pathol 149: 1941-1952, 1996.
35. Ohmori T, Podack ER, Nishio K, et al. Apoptosis of lung cancer cells caused by some anti-cancer agents (MMC, CPT-11, ADM) is inhibited by bcl-2, Biochem Biophys Res Commun 192: 30-36, 1993.
36. Miura I, Graziano SL, Cheng JQ, Doyle LA, Testa JR. Chromosome alterations in human small cell lung cancer: frequent involvement of 5q, Cancer Res 52: 1322-1328, 1992.
37. Reeve JG, Payne JA, Bleehen NM, Production of immunoreactive insulin-like growth factor-I (IGF-I) and IGF-I binding proteins by human lung tumours. Br J Cancer 61: 727-731, 1990.
38. Minuto F, Del Monte P, Barreca A, Fortini P, Cariola G, Catrambone G, Giordano G, Evidence for an increased somatomedin-C/insulin-like growth factor I content in primary human lung tumors. Cancer Res 46: 985-988, 1986.
39. Yu H, Spitz MR, Mistry J, Gu J, Hong WK, Wu X. Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst 91: 151-156, 1999.
40. Matthews W, Jordan CT, Wiegand GW, Pardoll D, Lemischka IR. A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations. Cell 65: 1143-1152, 1991.
41. Ashman LK. The biology of stem cell factor and its receptor C-kit. Int J Biochem Cell Biol 31: 1037-1051, 1999.
42. Linnekin D. Early signaling pathways activated by c-Kit in hematopoietic cells. Int J Biochem Cell Biol 31: 1053-1074, 1999.
43. Hibi K, Takahashi T, Sekido Y, Ueda R, Hida T, Ariyoshi Y, Takagi H. Coexpression of the stem cell factor and the c-kit genes in small-cell lung cancer. Oncogene 6: 2291-2296, 1991.
44. Sekido Y, Obata Y, Ueda R, Hida T, Suyama M, Shimokata K, Ariyoshi Y, Takahashi T. Preferential expression of c-kit protooncogene transcripts in small cell lung cancer. Cancer Res 51: 2416-2419, 1991.
45. Rygaard K, Nakamura T, Spang-Thomsen M. Expression of the proto-oncogenes c-met and c-kit and their ligands, hepatocyte growth factor/scatter factor and stem cell factor, in SCLC cell lines and xenografts. Br J Cancer 67: 37-46, 1993.
46. Plummer H III, Catlett J, Leftwich J, Armstrong B, Carlson P, Huff T, Krystal G. c-myc expression correlates with suppression of c-kit protooncogene expression in small cell lung cancer cell lines. Cancer Res 53: 4337-4342, 1993.
47. Sekido Y, Takahashi T, Ueda R, et al. Recombinant human stem cell factor mediates chemotaxis of small-cell lung cancer cell lines aberrantly expressing the c-kit protooncogene. Cancer Res 53: 1709-1714, 1993.
48. Krystal GW, Hines SJ, Organ CP. Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. Cancer Res 56: 370-376, 1996.
49. Yamanishi Y, Maeda H, Hiyama K, Ishioka S, Yamakido M. Specific growth inhibition of small-cell lung cancer cells by adenovirus vector expressing antisense c-kit transcripts. Jpn J Cancer Res 87: 534-542, 1996.
50. lyer A, Kmiecik TE, Park M, et al. Structure, tissue-specific expression, and transforming activity of the mouse met protooncogene. Cell Growth Differ 1: 87-95, 1990.
51. Rong S, Bodescot M, Blair D, et al. Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor. Mol Cell Biol 12: 5152-5158, 1992.
52. Faletto DL, Tsarfaty I, Kmiecik TE, Gonzatti M, Suzuki T, Vande Woude GF. Evidence for non-covalent clusters of the c-met proto-oncogene product. Oncogene 7: 1149-1157, 1992.
53. Maulik G, Kijima T, Ma PC, et al. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. Clin Cancer Res 8: 620-627, 2002.
54. Stella MC, Comoglio PM. HGF: a multifunctional growth factor controlling cell scattering. Int J Biochem Cell Biol 31: 1357-1362, 1999.
55. Norgaard P, Spang-Thomsen M, Poulsen HS. Expression and autoregulation of transforming growth factor beta receptor mRNA in small-cell lung cancer cell lines. Br J Cancer 73: 1037-1043, 1996.
56. Heldin CH, Miyazono K, Ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 390: 465-471, 1997.
57. Moore SM, Rintoul RC, Walker TR, Chilvers ER, Haslett C, Sethi T. The presence of a constitutively active phosphoinositide 3-kinase in small cell lung cancer cells mediates anchorage-independent proliferation via a protein kinase Band p70s6k-dependent pathway. Cancer Res 58: 5239-5247, 1998.
58. Carpenter CL, Cantley LC. Phosphoinositide kinases. Curr Opin Cell Biol 8: 153-158, 1996.
59. Rameh LE, Cantley LC. The role of phosphoinositide 3-kinase lipid products in cell function. J Biol Chem 274: 8347-8350, 1999.
60. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev 13: 2905-2927, 1999.
61. Vanhaesebroeck B, Alessi DR. The P13K-PDK1 connection: more than just a road to PKB. Biochem J 346 (Pt 3): 561-576, 2000.
62. Brazil DP, Hemmings BA. Ten years of protein kinase B signalling: a hard Akt to follow. Trends Biochem Sci 26: 657-664, 2001.
63. Kops GJ, Burgering BM. Forkhead transcription factors: new insights into protein kinase B (c-akt) signaling. J Mol Med 77: 656-665, 1999.
64. Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 96: 4240-4245, 1999.
65. Kim SK, Su LK, Oh Y, Kemp BL, Hong WK, Mao L. Alterations of PTEN/MMAC1, a candidate tumor suppressor gene, and its homologue, PTH2, in small cell lung cancer cell lines. Oncogene 16: 89-93, 1998.
66. Kohno T, Kawanishi M, Matsuda S, Ichikawa H, Takada M, Ohki M, Yamamoto T, Yokota J. Homozygous deletion and frequent allelic loss of the 21q11.1-q21.1 region including the ANA gene in human lung carcinoma. Genes Chromosomes Cancer 21: 236-243, 1998.
67. Forgacs E, Biesterveld EJ, Sekido Y, et al. Mutation analysis of the PTEN/MMAC1 gene in lung cancer. Oncogene 17: 1557-1565, 1998.
68. Hong TM, Yang PC, Peck K, Chen JJ, Yang SC, Chen YC, Wu CW. (eds) Profiling the downstream genes of tumor suppressor PTEN in lung cancer cells by complementary DNA microarray. Am J Respir Cell Mol Biol 23: 355-363, 2000.
69. Basu A. The potential of protein kinase C as a target for anticancer treatment. Pharmacol Ther 59: 257-280, 1993.
70. Blobe GC, Obeid LM, Hannun YA. Regulation of protein kinase C and role in cancer biology. Cancer Metastasis Rev 13: 411-431, 1994.
71. Lo SH, Chen LB. Focal adhesion as a signal transduction organelle. Cancer Metastasis Rev 13: 9-24, 1994.
72. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 69: 11-25, 1992.
73. Ambros VR, Chen LB, Buchanan JM. Surface ruffles as markers for studies of cell transformation by Rous sarcoma virus. Proc Natl Acad Sci USA 72: 3144-3148, 1975.
74. Bernal SD, Baylin SB, Shaper JH, Gazdar AF, Chen LB. Cytoskeleton-associated proteins of human lung cancer cells. Cancer Res 43: 1798-1808, 1983.
75. Salgia R, Li JL, Ewaniuk DS, et al. Expression of the focal adhesion protein paxillin in lung cancer and its relation to cell motility. Oncogene 18: 67-77, 1999.
76. Adler V, Yin Z, Tew KD, Ronai Z. Role of redox potential and reactive oxygen species in stress signaling. Oncogene 18: 6104-6111, 1999.
77. Kamata H, Hirata H. Redox regulation of cellular signalling. Cell Signal 11: 1-14, 1999.
78. Rahman I, MacNee W. Role of oxidants/antioxidants in smoking-induced lung diseases. Free Radic Biol Med 21: 669-681, 1996.
79. Huang P, Feng L, Oldham EA, Keating MJ, Plunkett W. Superoxide dismutase as a target for the selective killing of cancer cells. Nature 407: 390-395, 2000.
80. Pyke C, Ralfkiaer E, Tryggvason K, Dano K. Messenger RNA for two type IV collagenases is located in stromal cells in human colon cancer. Am J Pathol 142: 359-365, 1993.
81. Heppner KJ, Matrisian LM, Jensen RA, Rodgers WH. Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. Am J Pathol 149: 273-282, 1996.
82. Michael M, Babic B, Khokha R. Expression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small-cell lung cancer. J Clin Oncol 17: 1802-1808, 1999.
83. Cox G, Jones JL, Walker RA, Steward WP, O'Byrne KJ. Angiogenesis and non-small cell lung cancer. Lung Cancer 27: 81-100, 2000.
84. Junker K, Wiethege T, Muller KM. Pathology of small-cell lung cancer. J Cancer Res Clin Oncol 126: 361-368, 2000.
85. Zakowski MF. Pathology of small cell carcinoma of the lung. Semin Oncol 30: 3-8, 2003.
86. Travis WD. Pathology of lung cancer. Clin Chest Med 23: 65-81, viii, 2002.
87. Travis WD, Linnoila RI, Tsokos MG, et al. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am J Surg Pathol 15: 529-553, 1991.
88. Doria MI Jr, Montag AG, Franklin WA. Immunophenotype of small cell lung carcinoma. Expression of NKH-1 and transferrin receptor and absence of most myeloid antigens. Cancer 62: 1939-1945, 1988.
89. Mountain CF. Clinical biology of small cell carcinoma: relationship to surgical therapy. Semin Oncol 5: 272-279, 1978.
90. Lopez-Encuentra A, Bulzebruck H, Feinstein AR. Tumor staging and classification in lung cancer, Summary of the international symposium. Madrid, Spain, 3-4 December 1999. Lung Cancer 29: 79-83, 2000.
91. Brahmer JR, Ettinger DS. Carboplatin in the Treatment of Small Cell Lung Cancer. Oncologist 3: 143-154, 1998.
92. Pignon JP, Arriagada R, Ihde DC, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 327: 1618-1624, 1992.
93. Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol 10: 890-895, 1992.
94. Turrisi AT, III, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 340: 265-271, 1999.
95. Bonner JA, Sloan JA, Shanahan TG, et al. Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma. J Clin Oncol 17: 2681-2691, 1999.
96. Takada M, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol 20: 3054-3060, 2002.
97. Murray N, Coy P, Pater JL, et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 11: 336-344, 1993.
98. Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic S. Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: a randomized study. J Clin Oncol 15: 893-900, 1997.
99. Perry MC, Eaton WL, Propert KJ, et al. Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung. N Engl J Med 316: 912-918, 1987.
100. Perry MC, Herndon JE III, Eaton WL, Green MR. Thoracic radiation therapy added to chemotherapy for small-cell lung cancer: an update of Cancer and Leukemia Group B Study 8083. J Clin Oncol 16: 2466-2467, 1998.
101. Work E, Nielsen OS, Bentzen SM, Fode K, Palshof T. Randomized study of initial versus late chest irradiation combined with chemotherapy in limited-stage small-cell lung cancer. Aarhus Lung Cancer Group. J Clin Oncol 15: 3030-3037, 1997.
102. Skarlos DV, Samantas E, Briassoulis E, et al. Randomized comparison of early versus late hyperfractionated thoracic irradiation concurrently with chemotherapy in limited disease small-cell lung cancer: a randomized phase II study of the Hellenic Cooperative Oncology Group (HeCOG). Ann Oncol 12: 1231-1238, 2001.
103. Sorensen HR, Lund C, Alstrup P. Survival in small cell lung carcinoma after surgery. Thorax 41: 479-482, 1986.
104. Shah SS, Thompson J, Goldstraw P. Results of operation without adjuvant therapy in the treatment of small cell lung cancer. Ann Thorac Surg 54: 498-501, 1992.
105. Hayata Y. [Future of thoracic surgery, especially of pulmonary surgery (author's transl)]. Nippon Kyobu Geka Gakkai Zasshi 26: 242-248, 1978.
106. Shields TW, Higgins GA Jr, Matthews MJ, Keehn RJ. Surgical resection in the management of small cell carcinoma of the lung. J Thorac Cardiovasc Surg 84: 481-488, 1982.
107. Karrer K, Ulsperger E. Surgery for cure followed by chemotherapy in small cell carcinoma of the lung. For the ISC-Lung Cancer Study Group. Acta Oncol 34: 899-906, 1995.
108. Davis S, Crino L, Tonato M, Darwish S, Pelicci PG, Grignani F. A prospective analysis of chemotherapy following surgical resection of clinical stage I-II small-cell lung cancer. Am J Clin Oncol 16: 93-95, 1993.
109. Massone PP, Infante M, Lequaglie C, Magnani B, Ferro F, Conti B, Cataldo I. [Surgery in the treatment of metachronous homolateral non-small cell lung cancer]. Chir Ital 52: 533-540, 2000.
110. Lucchi M, Mussi A, Chella A, Janni A, Ribechini A, Menconi GF, Angeletti CA. Surgery in the management of small cell lung cancer. Eur J Cardiothorac Surg 12: 689-693, 1997.
111. Ohta M, Hara N, Ichinose Y, Motohiro A, Takeo S, Miyake J. The role of surgical resection in the management of small cell carcinoma of the lung. Jpn J Clin Oncol 16: 289-296, 1986.
112. Osterlind K, Hansen M, Hansen HH, Dombernowsky P. Influence of surgical resection prior to chemotherapy on the long-term results in small cell lung cancer. A study of 150 operable patients. Eur J Cancer Clin Oncol 22: 589-593, 1986.
113. Hara N, Ohta M, Ichinose Y, Motohiro A, Kuda T, Asoh H, Kawasaki M. Influence of surgical resection before and after chemotherapy on survival in small cell lung cancer. J Surg Oncol 47: 53-61, 1991.
114. Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346: 85-91, 2002.
115. Sculier JP, Berghmans T, Castaigne C, Luce S, Sotiriou C, Vermylen P, Paesmans M. Maintenance chemotherapy for small cell lung cancer: a critical review of the literature. Lung Cancer 19: 141-151, 1998.
116. Kristjansen PE, Hansen HH. Prophylactic cranial irradiation in small cell lung cancer-an update. Lung Cancer 12 (Suppl 3): S23-S40, 1995.
117. Arriagada R, Le Chevalier T, Borie F, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. J Natl Cancer Inst 87: 183-190, 1995.
118. Gregor A, Cull A, Stephens RJ, et al. Prophylactic cranial irradiation is indicated following complete response to induction therapy in small cell lung cancer: results of a multicentre randomised trial. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) and the European Organization for Research and Treatment of Cancer (EORTC). Eur J Cancer 33: 1752-1758, 1997.
119. Negoro S, Fukuoka M, Niitani H, et al. [A phase II study of CPT-11, a camptothecin derivative, in patients with primary lung cancer. CPT-11 Cooperative Study Group]. Gan To Kagaku Ryoho 18: 1013-1019, 1991.
120. Masuda N, Fukuoka M, Kusunoki Y, et al. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 10: 1225-1229, 1992.
121. Kudoh S, Fujiwara Y, Takada Y, Yamamoto H, Kinoshita A, Ariyoshi Y, Furuse K, Fukuoka M. Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung Cancer Group. J Clin Oncol 16: 1068-1074, 1998.
122. Ardizzoni A, Hansen H, Dombernowsky P, et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol 15: 2090-2096, 1997.
123. Levitan N, Dowlati A, Shina D, et al. Multi-institutional phase 1/11 trial of paclitaxel, cisplatin, and etoposide with concurrent radiation for limited-stage small-cell lung carcinoma. J Clin Oncol 18: 1102-1109, 2000.
124. Perez-Soler R, Glisson BS, Lee JS, Fossella FV, Murphy WK, Shin DM, Hong WK. Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan. J Clin Oncol 14: 2785-2790, 1996.
125. Schiller JH, Kim K, Hutson P, DeVore R, Glick J, Stewart J, Johnson D. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial. J Clin Oncol 14: 2345-2352, 1996.
126. von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 17: 658-667, 1999.
127. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 277: 665-667, 1979.
128. Parness J, Horwitz SB. Taxol binds to polymerized tubulin in vitro. J Cell Biol 91: 479-487, 1981.
129. Ettinger DS, Finkelstein DM, Sarma RP, Johnson DH. Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 13: 1430-1435, 1995.
130. Kirschling RJ, Grill JP, Marks RS, Paclitaxel and G-CSF in previously untreated patients with extensive stage small-cell lung cancer: a phase 11 study of the North Central Cancer Treatment Group. Am J Clin Oncol 22: 517-522, 1999.
131. Greco FA, Hainsworth JD. Paclitaxel, carboplatin, and oral etoposide in the treatment of small cell lung cancer. Semin Oncol 23: 7-10, 1996.
132. Bunn PA Jr, Kelly K. A phase I study of cisplatin, etoposide, and paclitaxel in small cell lung cancer. Semin Oncol 24: S12-144 and S112-148, 1997.
133. Smyth JF, Smith IE, Sessa C, Schoffski P, Wanders J, Franklin H, Kaye SB. Activity of docetaxel (Taxotere) in small cell lung cancer. The Early Clinical Trials Group of the EORTC. Eur J Cancer 30A: 1058-1060, 1994.
134. Cormier Y, Eisenhauer E, Muldal A, et al. Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC). A study of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 5: 283-285, 1994.
135. Jassem J, Karnicka-Mlodkowska H, van Pottelsberghe C, et al. Phase II study of vinorelbine (Navelbine) in previously treated small cell lung cancer patients. EORTC Lung Cancer Cooperative Group. Eur J Cancer 29A: 1720-1722, 1993.
136. Furuse K, Kubota K, Kawahara M, Phase II study of vinorelbine in heavily previously treated small cell lung cancer. Japan Lung Cancer Vinorelbine Study Group. Oncology 53: 169-172, 1996.
137. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2: 561-566, 1996.
138. Krystal GW, Honsawek S, Litz J, Buchdunger E. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin Cancer Res 6: 3319-3326, 2000.
139. Kijima T, Maulik G, Ma PC, et al. Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells. Cancer Res 62: 6304-6311, 2002.
140. Soria JC, Johnson BE, Chevalier TL. Imatinib in small cell lung cancer. Lung Cancer 41 (Suppl 1): S49-S53, 2003.
141. Brown PD. Matrix metalloproteinase inhibitors: a novel class of anticancer agents. Adv Enzyme Regul 35: 293-301, 1995.
142. de Cupis A, Ciomei M, Pirani P, Ferrera A, Ardizzoni A, Favoni RE. Anti-insulin-like growth factor-I activity of a novel polysulphonated distamycin A derivative in human lung cancer cell lines. Br J Pharmacol 120: 537-543, 1997.
143. O'Reilly MS, Holmgren L, Shing Y, Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79: 315-328, 1994.
144. Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Brem H, Folkman J. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 348: 555-557, 1990.